Evidence map›Paper›PMID 41788626›Full record

ArticleFrontiers in molecular biosciences2026

Quantum chemical profiling of protein mutations via fragment-based DFT.

Alejandro Leyva, M Khalid Khan Niazi

Abstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alejandro LeyvaDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, United States.
M Khalid Khan NiaziDepartment of Pathology, The Ohio State University, Columbus, OH, United States.

Funding

An ensemble deep learning model for tumor bud detection and risk stratification in colorectal carcinoma.R01CA276301 · NCI · OHIO STATE UNIVERSITY · PI Wei Chen, Muhammad Khalid Khan Niazi · 2023 to 2026
$2.0M
NCI NIH HHS R01 CA276301
6 · The paper itself

Abstract

Missense mutations have been extensively studied in tumor-suppressing antigens (TP53) to understand oncogenesis within malignant epithelial cells. Using Whole Exome Sequencing (WXS), missense mutations can be profiled into protein sequences to identify the most common variants in tumor samples. Since most mutations arise randomly, it is necessary to isolate those that produce dysfunctional proteins within large cohorts. Using threading and generative algorithms such as AlphaFold and ColabFold, large cohorts of WXS information can be converted into computationally analyzable structures. By evaluating both high- and low-confidence regions in these structures, these antigens can be studied en masse using pipelines that generate analytical inputs for quantum chemistry analysis. We created a pipeline that processed whole-exome sequencing (WXS) data and selected 28 representative TP53 missense mutants from the TCGA-BRCA cohort for quantum-chemical feasibility analysis. These structures were systematically cleaned using tools such as OpenBabel and AmberTools, and each was prepared for Natural Population Analysis (NPA), Electrostatic Potential (ESP) calculations, and Highest and Lowest Occupied Molecular Orbital (HOMO/LUMO) evaluation within Q-Chem. Using this pipeline, population genomics can be integrated with chemoinformatics to analyze electron density concentrations and generate hypothesis-generating electronic descriptors associated with protein dysfunction. By modifying the generated inputs, additional analyses such as Fukui orbitals, chemical shifts, and Raman shifts can also be performed. This provides a computational means to probe electronic properties not readily accessible at scale using experimental techniques.

Indexed as

AlphaFoldgenomicsquantum chemistrystructural biologywhole exome sequencing

Identifiers

PMID41788626
PMCPMC12956648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.